AZN Astrazeneca Plc

By Ed Ballard

LONDON--British-Swedish drugmaker AstraZeneca PLC (AZN.LN) said Thursday it received approval from the U.S. Food and Drug Administration for Xigduo XR as a daily treatment for type 2 diabetes.

"The addition of Xigduo XR to our U.S. diabetes portfolio is further evidence of AstraZeneca's commitment to develop new treatment options for patients with type 2 diabetes," said Elisabeth Björk, head of Cardiovascular & Metabolism at AstraZeneca's Global Medicines Development arm.

The drug, a combination of glucose-lowering agents dapagliflozin and metformin hydrochloride, has already been approved in Australia for adults with the condition.

Write to Ed Ballard at ed.ballard@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires